Method of enhancing antibody-dependent cell-mediated cytotoxicity (ADCC)

Abstract

Methods of preferentially enhancing in a subject an antibody-dependent cell-mediated cytotoxicity (ADCC) antibody response over a neutralizing antibody response to a vaccine for an infectious agent using herpesvirus entry mediator (HVEM) agonists, and related compositions.

Description

[0001] Statement of Government Support [0002] This invention was made with government support under Grant No. AI117321 awarded by the National Institutes of Health. The government has certain rights in this invention. Background technique [0003] Worldwide, more than 3.7 billion people are infected with herpes simplex virus type 1 (HSV-1) and approximately 400 million people are infected with HSV type 2 (HSV-2) (Looker et al., 2015; Roberts et al., 2003). HSV-1 is the leading cause of gingivostomatitis, a leading cause of corneal infectious blindness and fatal sporadic encephalitis, and has become a more common cause of primary genital herpes in the United States and other developed countries (Roberts et al., 2003). HSV-2 remains the leading cause of genital herpes worldwide and is a major cofactor in the HIV epidemic (Looker et al., 2017). Both serotypes remain latent in the dorsal root ganglion (DRG) with relatively frequent subclinical and clinical reactivation, resul...

AI Technical Summary

Problems solved by technology

In a subsequent field trial involving only doubly seronegative women, partial protection against genital HSV-1 was observed, but no protection against HSV-2 disease, and no protection against HSV-1 or HSV-2 infection Protection (Belshe et al., 2012)

Images